231 related articles for article (PubMed ID: 33895011)
1. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Bedke J; Maas M
Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
[No Abstract] [Full Text] [Related]
2. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
Niegisch G
N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
[No Abstract] [Full Text] [Related]
3. Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2021 Aug; 4(4):670. PubMed ID: 33994337
[No Abstract] [Full Text] [Related]
4. Enfortumab Vedotin in Advanced Urothelial Carcinoma.
Yeon SH; Lee HJ
N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440
[No Abstract] [Full Text] [Related]
5. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
Petrylak DP; Powles T; Rosenberg JE
N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441
[No Abstract] [Full Text] [Related]
6. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
7. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
Wang L; Shi G; Zhao G; He W; Cen Z; Xu F
Anticancer Drugs; 2023 Apr; 34(4):473-478. PubMed ID: 36730481
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
[TBL] [Abstract][Full Text] [Related]
12. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
[TBL] [Abstract][Full Text] [Related]
13. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
14. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
15. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
16. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
[TBL] [Abstract][Full Text] [Related]
17. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
18. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
[TBL] [Abstract][Full Text] [Related]
19. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
20. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
[No Abstract] [Full Text] [Related]
[Next] [New Search]